Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2014

Wilson Melissa A, Zhao Fengmin, Letrero Richard, D'Andrea Kurt, Rimm David L, Kirkwood John M, Kluger Harriet M, Lee Sandra J, Schuchter Lynn M, Flaherty Keith T, Nathanson Katherine L

Abstract excerpt

PURPOSE: Sorafenib is an inhibitor of VEGF receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF kinases, amongst others. We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel ± sorafenib (CP vs. CPS) EXPERIMENTAL DESIGN: Pretreatment tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Niacinamide

Share to Paclitaxel

Share to Phenylurea Compounds

Share to Sorafenib

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 24714776
DOI: 10.1158/1078-0432.CCR-14-0093
PMCID: PMC4058354

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.PMID 24714776Read ↗

Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.Semantic proximity Read ↗

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.Semantic proximity Read ↗

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patientsSemantic proximity Read ↗

Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.Semantic proximity Read ↗

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.Semantic proximity Read ↗

Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma.Semantic proximity Read ↗

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.Semantic proximity Read ↗

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.Semantic proximity Read ↗

The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response.Semantic proximity Read ↗

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read ↗

Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.Semantic proximity Read ↗

Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.